{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:33:55Z","timestamp":1759160035038,"version":"3.40.4"},"reference-count":8,"publisher":"S. Karger AG","issue":"2-3","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; The minimal inhibitory concentrations (MICs) of erythromycin, azithromycin, clarithromycin, telithromycin, tetracycline, doxycycline, ciprofloxacin, ofloxacin, norfloxacin, levofloxacin, gemifloxacin and moxifloxacin against 78 &lt;i&gt;Neisseria gonorrhoeae &lt;\/i&gt;and 31 &lt;i&gt;Ureaplasma urealyticum&lt;\/i&gt; strains, which were isolated from patients with urethritis in Istanbul, were determined and compared. Additionally, the activities of penicillin and ceftriaxone against &lt;i&gt;N. gonorrhoeae&lt;\/i&gt; strains were explored. &lt;i&gt;Methods:&lt;\/i&gt; MICs were determined by agar and broth dilution methods for N. gonorrhoeae and U. urealyticum, respectively. &lt;i&gt;Results:&lt;\/i&gt; The susceptibility rates for penicillin and tetracycline in &lt;i&gt;N. gonorrhoeae&lt;\/i&gt; strains were 35.9 and 24.3%, respectively. All gonococcal strains were susceptible to ceftriaxone, with very low MICs (MIC&lt;sub&gt;90&lt;\/sub&gt; 0.008 \u00b5g\/ml). Telithromycin was highly active against &lt;i&gt;N. gonorrhoeae&lt;\/i&gt; and &lt;i&gt;U. urealyticum&lt;\/i&gt; strains (MIC&lt;sub&gt;90&lt;\/sub&gt; 0.25 \u00b5g\/ml for both). Ciprofloxacin was the most active quinolone against &lt;i&gt;N. gonorrhoeae&lt;\/i&gt; (MIC&lt;sub&gt;90&lt;\/sub&gt; 0.008 \u00b5g\/ml) while quinolone resistance was detected in a single strain (1.3%). &lt;i&gt;Conclusions:&lt;\/i&gt; Tetracycline and penicillin should not be the option in empirical treatment of &lt;i&gt;N. gonorrhoeae&lt;\/i&gt; infections due to the very low susceptibility rates. Ceftriaxone continues to be the first choice antibiotic in the treatment of gonococcal urethritis.<\/jats:p>","DOI":"10.1159\/000085616","type":"journal-article","created":{"date-parts":[[2005,5,11]],"date-time":"2005-05-11T13:28:20Z","timestamp":1115818100000},"page":"89-92","source":"Crossref","is-referenced-by-count":4,"title":["Susceptibilities of &lt;i&gt;Neisseria gonorrhoeae&lt;\/i&gt; and &lt;i&gt;Ureaplasma urealyticum&lt;\/i&gt; Isolates from Male Patients with Urethritis to Several Antibiotics Including Telithromycin"],"prefix":"10.1159","volume":"51","author":[{"given":"Derya","family":"Ayd\u0131n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer","family":"K\u00fc\u00e7\u00fckbasmac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevriye","family":"G\u00f6n\u00fcll\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zerrin","family":"Akta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10156-002-0176-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F39.5.669"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000077889"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097%2F00007435-199809000-00013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2FBF01646419"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159%2F000069789"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F45.suppl_3.67"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2800%2900180-2"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:53:23Z","timestamp":1745466803000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000085616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":8,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000085616","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2005]]}}}